Metastatic Ovarian Serous Adenocarcinoma Clinically Presenting as Inflammatory Breast Cancer

Table 1

Summary of some useful biomarkers to differentiate primary breast cancer from metastatic ovarian cancer [4, 8–13].

IHC marker	Breast cancer	Ovarian cancer
CA125	16% of breast cancers show weak and focal CA125 immunopositivity	~90% of ovarian tumors CA125 positive, with mostly strong and diffuse staining
WT1	WT1 not expressed or very rarely expressed in breast cancer	WT1 expressed in 76% of ovarian cancer and 94% of ovarian serous adenocarcinomas
GCDFP-15	GCDFP-15 expressed in ~71% of metastatic breast cancers	All primary ovarian tumors and metastatic ovarian tumors negative for GCDFP-15
PAX8	PAX8 expressed 0-6.02% of breast tumors, with weak staining seen in some grade III invasive ductal carcinomas	79% or higher PAX8 immunopositivity in ovarian tumors
GATA-3	GATA-3 expressed in ~55-95% of different breast cancer subtypes	~6% GATA-3 expression in different ovarian tumors